Prism Medico & Pharmacy shareholders approved all 8 resolutions at its 24th Annual General Meeting on September 19, 2026, with each resolution receiving 99.99% votes in favour, per the scrutinizer's report submitted on September 22, 2026.

The meeting was held through Video Conferencing/Other Audio Visual Means at 12:30 pm. Mrs. Sakshi Laller, Wholetime Director, chaired the proceedings, which concluded at 12:42 pm. As on the record date of September 12, 2026, the company had 4,220 shareholders. Remote e-voting ran from 9:00 am on September 16, 2026 to 5:00 pm on September 18, 2026, facilitated by National Securities Depositories Limited (NSDL). M/s. M.R. Chechi & Associates, Practicing Company Secretaries, served as scrutinizer, with votes unblocked on September 19, 2026 at 2:12 pm after the conclusion of the AGM.

Voting results: ordinary business

The three ordinary business resolutions each recorded a consolidated vote of 28,03,095 in favour (99.99%) against 38 votes against (0.01%), with no invalid votes. The resolutions and their consolidated tallies are as follows:

Voting results: special business

Five special business resolutions were also put to vote, covering governance appointments and the strategic investment in M/s. Infuze Well Private Limited. Resolutions 5 and 8 excluded votes cast by specified related parties, as they were deemed interested parties.

For Item 5, votes cast by Mrs. Sejal S Nashatar, Mr. Harsh Jentibhai Rupareliya, Mrs. Shilpa Harsh Rupareliya, and Mr. Raju Tyagi were excluded as interested parties. For Item 8, votes cast by Mrs. Narish and Mr. Anil Kumar were similarly excluded.

Strategic investment in Infuze Well

A significant portion of the special business centred on approving transactions related to M/s. Infuze Well Private Limited. Shareholders authorised the variation in objects of the Preferential Issue previously approved at the Extraordinary General Meeting on March 20, 2026, the investment of funds in Infuze Well securities under Section 186 of the Companies Act, 2013, subscription to equity shares of Infuze Well as a material related party transaction, and general approval for related party transactions. All four Infuze Well-related resolutions passed with no invalid votes.

Governance and audit appointments

Mr. Davender Singh (DIN: 09447213), who retired by rotation, was re-appointed as Director. M/s. Garg Mendiratta and Associates, Chartered Accountants, were re-appointed as statutory auditors with remuneration fixed by the members. M/s. SDK & Associates, Practicing Company Secretaries, were appointed as Secretarial Auditors for a five-year term from FY27 to FY31. All poll papers and relevant records were sealed and handed over to the Company Secretary for safe keeping following the conclusion of the voting process.

Prism Medico & Pharmacy has scheduled its 24th Annual General Meeting (AGM) for Saturday, September 19, 2026. The company seeks shareholder approval for a strategic investment of up to ₹23 crore in M/s. Infuze Well Private Limited (IWPL). This follows a Board of Directors meeting held on Monday, August 24, 2026, at its registered office in Sirmaur, Himachal Pradesh.

The session concluded with the approval of the Director’s Report and annexures for the financial year ended March 31, 2026. This approval paves the way for the announcement of the company’s annual financial results and the finalization of the AGM agenda.

Annual General Meeting Details

The board fixed the date for the AGM as Saturday, September 19, 2026. The meeting will be conducted via Video Conferencing or Other Audio-Visual Means, starting at 12:30 pm.

Key logistical dates approved by the board include:

• Register Closure: The Register of Members and Share Transfer Books will remain closed from September 13, 2026, to September 19, 2026 (both days inclusive).
• E-Voting Cut-off: September 12, 2026, is the cut-off date for shareholders to record their entitlement to cast electronic votes.
• Scrutinizer: Mr. Mast Ram Chechi, proprietor of M/s. M. R. Chechi and Associates (Company Secretaries, Chandigarh), was appointed as the scrutinizer for the e-voting process.

E-Voting Schedule

Shareholders can participate in remote e-voting during the specified window. The timeline is as follows:

Auditor Appointments

The board considered and recommended the following auditor appointments:

• Statutory Auditors: Re-appointment of M/s. Garg Mendiratta and Associates (Chartered Accountants) with remuneration fixed.
• Secretarial Auditors: Appointment of M/s. SDK & Associates (Practicing Company Secretaries) for five financial years, from FY27 to FY31.

Preferential Issue Variation and Strategic Investment

A significant corporate governance update was the approval of a variation in the objects of the Preferential Issue and the utilization of its proceeds. This change modifies the terms originally approved by members in the Extraordinary General Meeting held on March 20, 2026.

The board proposed diverting ₹23 crore of the preferential issue proceeds—originally earmarked for plant machinery and civil structures—to acquire a controlling stake in IWPL. IWPL is setting up a Large Volume Parenteral (LVP) manufacturing facility in Naraingarh, Haryana.

Transaction Details

The investment constitutes a material related party transaction as IWPL is wholly owned by Mrs. Sakshi Laller, Whole-Time Director of Prism Medico, and her immediate family. Mrs. Laller holds 19.40% of IWPL’s paid-up equity share capital. Consequently, related parties are required to abstain from voting on this resolution.

The deployment of proceeds towards this revised object is contingent upon the receipt of balance consideration payable on the exercise of convertible warrants allotted in the earlier preferential issue. The company has received ₹17.5 crore till date against the total ₹25 crore raised, with ₹7.5 crore remaining to be realized upon warrant exercise.

Additionally, the board recommended investing the company’s funds in accordance with Section 186 of the Companies Act, 2013, noting that the proposed investment exceeds the statutory limits prescribed under Section 186(2).

The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.